Type 2 diabetes therapy. A pathophysiologically based approach

Postgrad Med. 2002 Mar;111(3):83-4, 87-92, 95. doi: 10.3810/pgm.2002.03.1140.

Abstract

The dramatic increase in the number of classes of oral antidiabetic agents has provided physicians with more tools to help patients manage type 2 diabetes. Of course, glycemic control must remain paramount when choosing an oral agent. However, the mechanism of action of an agent, its side effect profile, and the potential for various nonglycemic benefits may help determine which is the best drug for an individual patient.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Benzamides / therapeutic use
  • Biguanides / therapeutic use
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Sulfonylurea Compounds / therapeutic use
  • Thiazoles / therapeutic use
  • Thiazolidinediones*
  • alpha-Glucosidases / therapeutic use

Substances

  • Benzamides
  • Biguanides
  • Hypoglycemic Agents
  • Sulfonylurea Compounds
  • Thiazoles
  • Thiazolidinediones
  • meglitinide
  • 2,4-thiazolidinedione
  • alpha-Glucosidases